Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q4 2018 · 10-K
Revenue$43.77M$43.77M+3.8% vs Q4 2017 Net Income-$7.46M-$7.46MN/M vs Q4 2017 EPS Diluted-$0.18-$0.18N/M vs Q4 2017 Operating Income-$4,985,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,565,000N/M Margins · derivedOperating margin-11.4%+24.6 pt vs Q4 2017
Net margin-17.0%+24.7 pt vs Q4 2017
ended Dec 31, 2018 · filed Feb 26, 2019 · 57 d after period end